PD-217,014

PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α₂δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.^[1]

PD-217,014

Identifiers
IUPAC name (1α,3α,5α)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid
CAS Number	444088-20-4 Y
PubChem CID	10313401
ChemSpider	19264101
UNII	K2T93E812G
CompTox Dashboard (EPA)	DTXSID801030092
Chemical and physical data
Formula	C10H17NO2
Molar mass	183.251 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1C[C@@H]2[C@H]1C[C@](C2)(CC(=O)O)CN
InChI InChI=1S/C10H17NO2/c11-6-10(5-9(12)13)3-7-1-2-8(7)4-10/h7-8H,1-6,11H2,(H,12,13)/t7-,8+,10+ Key:NDDZVQRQVFTNSN-MBTKJCJQSA-N